BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8542246)

  • 1. Interferon and chronic myelogenous leukaemia.
    Lauta VM
    Med Oncol; 1995 Mar; 12(1):41-6. PubMed ID: 8542246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
    Beck JR; Guilhot J; Giles FJ; Aoki N; Wirt DP; Guilhot F
    Leuk Lymphoma; 2001 Mar; 41(1-2):117-24. PubMed ID: 11342363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon in chronic myeloid leukaemia: past and future.
    Guilhot F; Roy L; Saulnier PJ; Guilhot J
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):315-29. PubMed ID: 19959083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-alpha therapy for chronic myelogenous leukemia.
    Wetzler M; Kantarjian H; Kurzrock R; Talpaz M
    Am J Med; 1995 Oct; 99(4):402-11. PubMed ID: 7573097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia.
    Kloke O; Wandl U; Opalka B; Moritz T; Nagel-Hiemke M; Franz T; Becher R; Hirche H; Seeber S; Niederle N
    Eur J Haematol; 1992 Feb; 48(2):93-8. PubMed ID: 1547881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
    Angstreich GR; Matsui W; Huff CA; Vala MS; Barber J; Hawkins AL; Griffin CA; Smith BD; Jones RJ
    Br J Haematol; 2005 Aug; 130(3):373-81. PubMed ID: 16042686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
    Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
    Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: clinical responsiveness to recombinant IFN-alpha correlates with the degree of receptor down-regulation.
    Bartsch HH; Pfizenmaier K; Hanusch A; Scheurich P; Ucer U; Nagel GA
    Int J Cancer; 1989 Feb; 43(2):235-40. PubMed ID: 2521842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential treatment of Ph-positive chronic myeloid leukemia with interferon gamma and interferon alpha.
    Russo D; Fanin R; Zuffa E; Damiani D; Gallizia C; Michieli M; Testoni N; Benfenati D; Visani G; Zaccaria A
    Haematologica; 1990; 75(4):334-9. PubMed ID: 2125966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha in the treatment of chronic myeloid leukemia. A summary and an update of the Italian studies.
    Rosti G; De Vivo A; Zuffa E; Baccarani M
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S11-3. PubMed ID: 8769692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
    Cortes J; Kantarjian H; O'Brien S; Robertson LE; Pierce S; Talpaz M
    Am J Med; 1996 Apr; 100(4):452-5. PubMed ID: 8610733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of chronic myelogenous leukaemia with interferons.
    Talpaz M; Kurzrock R; Kantarjian H; Gutterman J
    Cancer Surv; 1989; 8(4):793-8. PubMed ID: 2701727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon alpha in the treatment of chronic myelogenous leukemia.
    Robak T
    Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma-IFN induced cell adhesion in chronic myelogenous leukemia cells.
    Grandér D; Xu B; Wang P; Einhorn S
    Leukemia; 1994 Feb; 8(2):299-304. PubMed ID: 7905942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; O'Brien S; Beran M; Koller C; Pierce S; Kornblau S; Estey E; Keating MJ; Talpaz M
    Leukemia; 1997 Oct; 11(10):1610-6. PubMed ID: 9324278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic myelogenous leukemia with interferons alpha and gamma.
    Kloke O; May D; Wandl U; Becher R; Opalka B; Beer U; Niederle N
    Blut; 1990 Jul; 61(1):45-6. PubMed ID: 2117476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
    Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
    Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic therapy of chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Gutterman J
    Oncology (Williston Park); 1987 Sep; 1(7):35-40, 48-9, 52. PubMed ID: 3152810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.
    Burchert A; Müller MC; Kostrewa P; Erben P; Bostel T; Liebler S; Hehlmann R; Neubauer A; Hochhaus A
    J Clin Oncol; 2010 Mar; 28(8):1429-35. PubMed ID: 20142590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.